Psychiatric Uses of Newer Anticonvulsants

Berigan, Timothy R.

doi:10.4088/pcc.v03n0207

Cited by 4 publications

(2 citation statements)

References 42 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, further research has been inconsistent regarding the purported antidepressant effect of GABA-B receptor binding [85]. Currently, the proven clinical efficacy of ACD in mood disorders continues to fuel the study of GABAergic modulation in this context [86].…”

Section: Expanding Views On the Neurobiology Of Depressionmentioning

confidence: 99%

Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines

Chávez-Castillo

Núñez

Nava

et al. 2019

Advances in Pharmacological Sciences

View full text Add to dashboard Cite

Depression is currently recognized as a crucial problem in everyday clinical practice, in light of ever-increasing rates of prevalence, as well as disability, morbidity, and mortality related to this disorder. Currently available antidepressant drugs are notoriously problematic, with suboptimal remission rates and troubling side-effect profiles. Their mechanisms of action focus on the monoamine hypothesis for depression, which centers on the disruption of serotonergic, noradrenergic, and dopaminergic neurotransmission in the brain. Nevertheless, views on the pathophysiology of depression have evolved notably, and the comprehension of depression as a complex neuroendocrine disorder with important systemic implications has sparked interest in a myriad of novel neuropsychopharmacological approaches. Innovative pharmacological targets beyond monoamines include glutamatergic and GABAergic neurotransmission, brain-derived neurotrophic factor, various endocrine axes, as well as several neurosteroids, neuropeptides, opioids, endocannabinoids and endovanilloids. This review summarizes current knowledge on these pharmacological targets and their potential utility in the clinical management of depression.

show abstract

Section: Expanding Views On the Neurobiology Of Depressionmentioning

confidence: 99%

Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines

Chávez-Castillo

Núñez

Nava

et al. 2019

Advances in Pharmacological Sciences

View full text Add to dashboard Cite

show abstract

“…Sir: Since the publication of a recent review of the psychiatric uses of newer anticonvulsants in the Companion, 1 2 new anticonvulsants have come to market. The first is levetiracetam, which is U.S. Food and Drug Administration-approved as an adjunctive agent in treating partial-onset seizures in adults with epilepsy.…”

Section: Uses Of Newer Anticonvulsants: An Updatementioning

confidence: 99%